Proteros Biostructures and Boehringer Ingelheim Enter into Protein Crystallography Agreement
News May 16, 2007
Under the terms of the agreement, which will run for 18 months, Proteros will receive research funding fees and success payments for the generation and analyzes of protein-ligand-structures of hits and evolved chemical entities from in-house Boehringer Ingelheim programs.
Proteros will apply its proprietary Free Mounting System (FMS™) and Picodropper™ technologies to maximize data quality and success rates, thus allowing rapid evolution of multiple hit series at Boehringer Ingelheim.
Financial details of the transaction were not disclosed.
Torsten Neuefeind, Ph.D., Chief Executive Officer of Proteros, stated, ”We are pleased to extend the scope of our long standing relationship with various sites of Boehringer Ingelheim. By taking advantage of Proteros’ experience and the industrialized processes enabling time- and cost-efficient protein-ligand-structure analyses, Boehringer Ingelheim complements its internal capabilities with our external expertise and access flexible resources. Especially when working with challenging chemical entities, Proteros’ Picodropper™ can make the difference between success and failure.”
Mr. Neuefeind continued: “This collaboration underscores Proteros’ expertise in the field of protein crystallography, and furthermore marks an important milestone in Proteros’ progress to further expand its client base in North America.”
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE